Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

As of late, AbbVie has pinned its growth hopes on its Humira follow-on treatments Skyrizi and Rinvoq, which grew sales to $11.7 billion and $6 billion last year, respectively.

Despite mixed quarterly results and increased R&D expenses, optimism stems from strong growth in Skyrizi, Rinvoq, and promising segments like Neuroscience and Oncology. AbbVie's strategic move ...

Its key drugs include Humira for treating rheumatoid arthritis, psoriasis, Crohn's disease and other conditions, and Skyrizi for treating plaque psoriasis, psoriatic arthritis, Crohn's disease and ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the ...